Megakaryocyte- and megakaryocyte precursor-related gene therapies

Blood

Volumn 127, Issue 10, 2016, Pages 1260-1268

  Wilcox, David A ^a,b,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; ALPHA2 INTEGRIN; ITGA2B PROTEIN, HUMAN;

CELL DIFFERENTIATION; CELL LINEAGE; CELLS BY BODY ANATOMY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; MEGAKARYOCYTE; MUTAGENESIS; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; TRANSGENE; ANIMAL; BIOSYNTHESIS; GENETICS; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MEGAKARYOBLAST; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; GENETIC THERAPY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTEGRIN ALPHA2; MEGAKARYOCYTE PROGENITOR CELLS; MEGAKARYOCYTES; TRANSGENES;

EID: 84960889147     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-607937     Document Type: Review

References (90)

1. Breton-Gorius J, Reyes F. Ultrastructure of human bone marrow cell maturation. Int Rev Cytol. 1976;46:251-321.
2. Ebbe S. Biology of megakaryocytes. Prog Hemost Thromb. 1976;3:211-229.
3. Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 1999; 147(6):1299-1312.
4. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115(12): 3348-3354.
5. Italiano JE Jr, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost. 2003;1(6):1174-1182.
6. Nurden AT. Platelet membrane glycoproteins: a historical review. Semin Thromb Hemost. 2014; 40(5):577-584.
7. Block KL, Ravid K, Phung QH, Poncz M. Characterization of regulatory elements in the 59-flanking region of the rat GPIIb gene by studies in a primary rat marrow culture system. Blood. 1994;84(10):3385-3393.
8. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR Jr, Wilson JM. Longterm improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science. 1991;254(5039):1802-1805.
9. Yao SN, Wilson JM, Nabel EG, Kurachi S, Hachiya HL, Kurachi K. Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci USA. 1991;88(18):8101-8105.
10. Anderson WF, Goldberg S, Kantoff P, Berg P, Eglitis M, Humphries RK. Attempts at gene therapy in beta-thalassemic mice. Ann N Y Acad Sci. 1985;445:445-451.
11. Steinmetz M. Immune response restored by gene therapy in mice. Nature. 1985;316(6023):14-15.
12. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475-480.
13. Wilcox DA, Olsen JC, Ishizawa L, Griffith M, White GC II. Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc Natl Acad Sci USA. 1999;96(17):9654-9659.
14. Shiraga M, Ritchie A, Aidoudi S, et al. Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin a IIb b 3 signaling. J Cell Biol. 1999;147(7):1419-1430.
15. Faraday N, Rade JJ, Johns DC, et al. Ex vivo cultured megakaryocytes express functional glycoprotein IIb-IIIa receptors and are capable of adenovirus-mediated transgene expression. Blood. 1999;94(12):4084-4092.
16. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood. 1995;85(2):402-413.
17. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994; 369(6481):533-538.
18. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients\ with Wiskott-Aldrich syndrome. Science. 2013; 341(6148):1233151.
19. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013; 341(6148):1233158.
20. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328(5978):562-564.
21. Machlus KR, Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol. 2013;201(6): 785-796.
22. Roth GJ, Yagi M, Bastian LS. The platelet glycoprotein Ib-V-IX system: regulation of gene expression. Stem Cells. 1996;14(suppl 1): 188-193.
23. Uzan G, Prenant M, Prandini MH, Martin F, Marguerie G. Tissue-specific expression of the platelet GPIIb gene. J Biol Chem. 1991;266(14): 8932-8939.
24. Holmes ML, Bartle N, Eisbacher M, Chong BH. Cloning and analysis of the thrombopoietininduced megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1. J Biol Chem. 2002;277(50):48333-48341.
25. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002; 21(21):3359-3367.
26. Ravid K, Beeler DL, Rabin MS, Ruley HE, Rosenberg RD. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Natl Acad Sci USA. 1991; 88(4):1521-1525.
27. Romeo PH, Prandini MH, Joulin V, et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature. 1990; 344(6265):447-449.
28. Wang X, Crispino JD, Letting DL, Nakazawa M, Poncz M, Blobel GA. Control of megakaryocytespecific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. EMBO J. 2002; 21(19):5225-5234.
29. Doi T, Greenberg SM, Rosenberg RD. Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. Mol Cell Biol. 1987;7(2):898-904.
30. Zhang C, Thornton MA, Kowalska MA, et al. Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein platelet factor 4 gene locus. Blood. 2001;98(3): 610-617.
31. Du LM, Nurden P, Nurden AT, et al. Platelettargeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun. 2013;4:2773.
32. Sullivan SK, Mills JA, Koukouritaki SB, et al. Highlevel transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2014;123(5): 753-757.
33. Nguyen HG, Yu G, Makitalo M, et al. Conditional overexpression of transgenes in megakaryocytes and platelets in vivo. Blood. 2005;106(5): 1559-1564.
34. Wilcox DA, White GC II. Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. J Thromb Haemost. 2003;1(11): 2300-2311.
35. Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. Br J Haematol. 2014;165(2):165-178.
36. Nurden AT, Nurden P. Inherited disorders of platelet function: selected updates. J Thromb Haemost. 2015;13(suppl 1):S2-S9.
37. Franchini M, Lippi G. NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia. Expert Rev Hematol. 2014;7(6):733-740.
38. White GC II. Congenital and acquired platelet disorders: current dilemmas and treatment strategies. Semin Hematol. 2006;43(1 suppl 1): S37-S41.
39. Flood VH, Johnson FL, Boshkov LK, et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer. 2005;45(7):971-975.
40. Niemeyer GP, Boudreaux MK, Goodman-Martin SA, Monroe CM, Wilcox DA, Lothrop CD Jr. Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation. Exp Hematol. 2003;31(12):1357-1362.
41. Wiegering V, Sauer K, Winkler B, Eyrich M, Schlegel PG. Indication for allogeneic stem cell transplantation in Glanzmann's thrombasthenia. Hamostaseologie. 2013;33(4):305-312.
42. Wiegering V, Winkler B, Langhammer F, et al. Allogeneic hematopoietic stem cell transplantation in Glanzmann thrombasthenia complicated by platelet alloimmunization. Klin Padiatr. 2011;223(3):173-175.
43. Wilcox DA, Olsen JC, Ishizawa L, et al. Megakaryocyte-targeted synthesis of the integrin b(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood. 2000;95(12): 3645-3651.
44. Fang J, Hodivala-Dilke K, Johnson BD, et al. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106(8): 2671-2679.
45. Fang J, Jensen ES, Boudreaux MK, et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci USA. 2011;108(23):9583-9588.
46. Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR. Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. J Thromb Haemost. 2004;2(11):1989-1997.
47. Kanaji S, Kuether EL, Fahs SA, et al. Correction of murine Bernard-Soulier syndrome by lentivirusmediated gene therapy. Mol Ther. 2012;20(3): 625-632.
48. Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: ectopic expression of urokinasetype plasminogen activator in platelets. Blood. 2003;102(3):926-933.
49. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010;16(1):20-32.
50. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447-1456.
51. High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia gene therapy. Haemophilia. 2014;20(suppl 4):43-49.
52. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF; Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med. 2001; 344(23):1735-1742.
53. Powell JS, Ragni MV, White GC II, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood. 2003; 102(6):2038-2045.
54. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vectormediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
55. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81(11):2925-2935.
56. Ye P, Thompson AR, Sarkar R, et al. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther. 2004;10(1): 117-126.
57. Sabatino DE, Lange AM, Altynova ES, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther. 2011;19(3): 442-449.
58. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-1574.
59. McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121(17):3335-3344.
60. Chuah MK, Nair N, VandenDriessche T. Recent progress in gene therapy for hemophilia. Hum Gene Ther. 2012;23(6):557-565.
61. Siner JI, Iacobelli NP, Sabatino DE, et al. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood. 2013;121(21):4396-4403.
62. Doering CB, Spencer HT. Replacing bad (F) actors: hemophilia. Hematology Am Soc Hematol Educ Program. 2014;2014(1):461-467.
63. Johnston JM, Denning G, Doering CB, Spencer HT. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Ther. 2013;20(6):607-615.
64. Wilcox DA, Shi Q, Nurden P, et al. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost. 2003;1(12):2477-2489.
65. Shi Q, Wilcox DA, Fahs SA, et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest. 2006;116(7):1974-1982.
66. Shi Q, Wilcox DA, Fahs SA, et al. Lentivirusmediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007;5(2):352-361.
67. Yarovoi HV, Kufrin D, Eslin DE, et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 2003;102(12): 4006-4013.
68. Gould J. Gene therapy: genie in a vector. Nature. 2014;515(7528):S160-S161.
69. Haberichter SL, Jozwiak MA, Rosenberg JB, Christopherson PA, Montgomery RR. The von Willebrand factor propeptide (VWFpp) traffics an unrelated protein to storage. Arterioscler Thromb Vasc Biol. 2002;22(6):921-926.
70. Haberichter SL, Jacobi P, Montgomery RR. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage. Blood. 2003;101(4):1384-1391.
71. Yarovoi H, Nurden AT, Montgomery RR, Nurden P, Poncz M. Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII. Blood. 2005;105(12):4674-4676.
72. Wang X, Shin SC, Chiang AF, et al. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. Mol Ther. 2015;23(4):617-626.
73. Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2014;229(8): 1005-1015.
74. Montecinos VP, Morales CH, Fischer TH, et al. Selective targeting of bioengineered platelets to prostate cancer vasculature: new paradigm for therapeutic modalities. J Cell Mol Med. 2015; 19(7):1530-1537.
75. Li J, Luo J, Luo YQ, et al. Overexpression of tumstatin in genetically modified megakaryocytes changes the proangiogenic effect of platelets. Transfusion. 2014;54(8):2106-2117.
76. Fang J, Yao M, Jing W, Sun B, Johnson BD, Wilcox DA. Platelets engineered to store interleukin-24 inhibited melanoma growth in mice [abstract]. J Thromb Haemost. 2015; 13(suppl S2):225. Abstract OR342.
77. Feng Q, Shabrani N, Thon JN, et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Rep. 2014;3(5):817-831.
78. Lambert MP, Sullivan SK, Fuentes R, French DL, Poncz M. Challenges and promises for the development of donor-independent platelet transfusions. Blood. 2013;121(17):3319-3324.
79. Wang Y, Hayes V, Jarocha D, et al. Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale. Blood. 2015;125(23): 3627-3636.
80. Greene TK, Lyde RB, Bailey SC, et al. Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy. J Thromb Haemost. 2014;12(12):2102-2112.
81. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16): 1185-1193.
82. Cavazzana-Calvo M, Fischer A. Efficacy of gene therapy for SCID is being confirmed. Lancet. 2004;364(9452):2155-2156.
83. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672.
84. Kaiser J. Gene therapy. Panel urges limits on X-SCID trials. Science. 2005;307(5715):1544-1545.
85. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348(3): 255-256.
86. Kaiser J. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science. 2003; 299(5606):495.
87. Bradford GB, Williams B, Rossi R, Bertoncello I. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol. 1997;25(5):445-453.
88. Biffi A, Bartolomae CC, Cesana D, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood. 2011;117(20):5332-5339.
89. Shi Q, Fahs SA, Wilcox DA, et al. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood. 2008; 112(7):2713-2721.
90. Neyman M, Gewirtz J, Poncz M. Analysis of the spatial and temporal characteristics of plateletdelivered factor VIII-based clots. Blood. 2008; 112(4):1101-1108.